GlobeNewsWire
22 Jul 2026, 10:47 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo clinical trial for advanced melanoma failed to reach statistical significance for its primary endpoint. — The failure of a 'potential blockbuster' drug in Phase III represents a significant loss of future revenue growth and a waste of R&D investment.
-0.80A securities fraud class action lawsuit has been filed against Regeneron and its executives, alleging they misled investors about the trial's success. — Litigation creates legal overhang, potential financial settlements, and reputational damage, though it is secondary to the clinical failure itself.
-0.30Which stocks this story touches
The company is facing a securities fraud class action lawsuit following the failure of a Phase III clinical trial and significant stock price drops.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
